A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)

• Status: Completed
• Trial end date: 2018-02-09
• Target enrollment: 0
• Participant gender: All

Summary

The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes. The purpose of this study is to assess the safety of the AID system and to test whether the AID System functions as it was designed to.

This study will last approximately 12-18 days, not including screening. Screening is required within 28 days prior to the start of the study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Insulin Lispro

Criteria

Inclusion Criteria:

• Participants with T1DM for at least 2 years and who have used an insulin delivery system for at least 1 year

• Have a body mass index of 18.5 to 35 kilogram per meter squared

• Have a hemoglobin A1c level ≥6.0% and ≤9.0%

Exclusion Criteria:

• Have known allergies or history of hypersensitivity to insulin lispro

• Have had an episode of severe hypoglycemia within the past 6 months

• Have had more than 1 episode of diabetic ketoacidosis in the past 6 months